You are here

Press Release Archive

 
- Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent fourth-quarter 2010 dividend on the company's common stock, payable December 1, 2010, to shareholders of record at the close of business on November 8, 2010. The fourth-quarter 2010 cash dividend will be the 288th consecutive quarterly dividend paid by Pfizer.

 
- Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were

 
- Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the commencement of a tender offer by its wholly owned subsidiary, Parker Tennessee Corp., for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated October 22, 2010, and

 
- New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia

(BUSINESS WIRE)--Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to

 
- Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines. Pfizer will acquire a 40 percent stake in Teuto and the companies will also enter into a series of commercial agreements. The partnership will enhance Pfizer's position in Brazil, a key emerging market, by

 
- Biocon and Pfizer Enter Into Global Commercialization Agreement

(BUSINESS WIRE)--Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Pfizer will have exclusive rights to commercialize these

 
- Alzheimer's Disease Caregivers Identify Memory Loss, Personal Safety and Confusion as Top Three Concerns Related to Progression of Their Loved One's Disease

(BUSINESS WIRE)--Results announced today from a national survey of Alzheimer's disease (AD) caregivers found that memory loss and confusion, which are cognitive symptoms, in addition to personal safety, are the greatest concerns related to the progression of their loved one's AD. In fact, 67 percent of AD caregivers surveyed said changes in cognitive symptoms were among their main concerns. The survey of 524 non-

 
- Pfizer to Acquire King Pharmaceuticals, Inc.

(BUSINESS WIRE)--Pfizer Inc.(NYSE: PFE) and King Pharmaceuticals, Inc. (NYSE: KG) today announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share, which represents a premium of approximately 40% to King's closing price as of October

 
- Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that data from a Phase 2 efficacy and safety study of tasocitinib (proposed INN name for CP-690,550), the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to

 
- Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets

(BUSINESS WIRE)--Pfizer Oncology will present new data across its portfolio representing novel approaches to researching treatments for patients with rare and difficult-to-treat cancers. These results will be presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October 8-12. "Pfizer (NYSE: PFE) has focused its oncology research on targeting molecular drivers and pathways in various cancers

 
- Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor

 
- Pfizer Reports Second-Quarter 2010 Results

(BUSINESS WIRE)-- ($ in millions, except per share amounts) Second-Quarter Year-to-Date 2010

 
- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Established Products, at the BMO Capital Markets 10th Annual Focus On Healthcare Conference on Thursday, August 5, 2010 at 11:15 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the "BMO

 
- Pfizer To Offer Free Public Access To Mental Health Assessment Tools To Improve Diagnosis And Patient Care

(BUSINESS WIRE)--As part of its commitment to improving the quality of patient care, Pfizer today announced that it will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders. For the first time, these users can directly access and download the Patient Health Questionnaire (PHQ) and the General Anxiety Disorder

 
- Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program; Some Studies Continue In Areas Of Unmet Medical Need

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain. The FDA’s request follows further consideration

 
- Pfizer And SMC Collaborate On Liver Cancer

(BUSINESS WIRE)--Samsung Medical Center and the world’s leading bio-pharmaceutical company Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer. The two organizations held a signing ceremony at the main conference hall located on the

 
- New Research Presented At Alzheimer’s Association International Conference On Alzheimer's Disease Indicates Alzheimer’s Disease May Lead To Increased Comorbid Conditions And Economic Burden

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer’s Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) from two podium and four poster presentations. This research indicates there may be potential for an increased risk of comorbid conditions, such as seizures,

 
- Pfizer To Present More Than 40 Abstracts On Pre-Clinical, Clinical And Outcomes Research At Alzheimer's Association International Conference On Alzheimer’s Disease

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present new data on its investigational compounds targeting various aspects of Alzheimer’s disease (AD), a complex degenerative brain disorder. New findings on the role of comorbidities, the burden of care and costs associated with AD, also will be discussed. These data, some in collaboration with our partners, will be presented at the Alzheimer's Association International Conference on

 
- Pfizer Strengthens Manufacturing Capabilities In Asia With Expansion Of Singapore Nutrition Plant

(BUSINESS WIRE)--Pfizer Inc. today announced a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children. This expansion, which brings the total investment in the plant to $372 million (U.S.), makes it one of the largest nutritional plants worldwide

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.